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THE LIMITATIONS OF CURRENT MALARIA TREATMENTS  
IN SUB-SAHARAN AFRICA 
 




Current malaria treatments are ineffective in sub-Saharan Africa due to 
problems beyond the disease. Approximately 90% of malaria mortalities occur in 
sub-Saharan Africa, and 77% percent of these are children under the age of five. 
At the same time, sub-Saharan Africa is also the recipient of 80% of international 
aid. With international malaria funding increasing in recent years, there must be 
an analysis on the practicability of funded interventions as malaria continues to 
be a tremendous burden in the region.  
 This review highlights the complexity of malaria pathology and its 
association with poverty that makes treatments ineffective. Available, frontline 
antimalarial drugs and insecticides have shown increased resistance that has 
spread throughout many malaria endemic regions. This resistance aggravates 
the disease as the parasite and the vector evolve, resulting in increased 
transmission, increased severity of symptoms, and a high risk of mortality. In 
addition, the heavily funded malaria vaccine under development by 
GlaxoSmithKline and PATH shows partial efficacy that languishes over time, 
putting to question the practicability of such heavily funded interventions. The 
  vi 
limitations of available treatments necessitates a holistic approach that responds 
to the economic state of endemic regions in order to effectively alleviate the 
burden of disease.  
An example of a holistic approach is the Multisectoral Action Framework 
for Malaria. This approach considers the socioeconomic development and fragile 
markets of endemic nations to encourage partnerships between governments 
and healthcare sectors in eradicating malaria. Although it will take years to 
demonstrate results, the burden of malaria calls for sustained efforts to alleviate 
the burden of the disease along with the poverty that perpetuates it. 
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Malaria begins with a female anopheles mosquito bite. During a blood 
meal, the malaria parasites are injected from the salivary glands of the mosquito, 
and into the blood stream of the human host (CDC (a), n.d.). Once in the blood 
stream, the parasites, known as sporozites mature and infect two hosts: the liver 
cells (hepatocytes) and the red blood cells (erythrocytes). In the liver cell, the 
parasites mature into schizonts. The schizonts then grow within the hepatocyte 
and eventually the cell bursts releasing merozoites. These merozoites then enter 
the blood stream, infecting the red blood cells. Some merozoites differentiate into 
sexual erythrocytic stages (gametocytes), which are responsible for infecting 
another mosquito that takes a blood meal from the infected host. Other 
merozoites, mature into trophozites then into schizonts, and eventually rupture 
releasing more merozoites that infect other red blood cells and the cycle 
continues (Miller, Ackerman, Su, & Wellems, 2013). This rupture is also known 
as schizogony (“Impact Malaria” n.d.). The parasites also undergo a maturation 
cycle within the mosquito that is not affected by their presence. 
After infection, the host individual may be asymptomatic for a period of 
time depending on the particular species of the parasite. The plasmodium 
parasite is the cause of human malaria and exists as four species: P. falciparum, 
P. malariae, P. ovale and P. vivax (CDC (a), n.d.). Following the parasites 
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incubation period within the host, symptoms such as cough, fatigue, malaise, 
shaking chills, arthralgia, and myalgia begin to manifest (Medscape, n.d.). 
Patients will typically clinically present with a simple headache.  The most 
common symptom of malarial infection, however, is intermittent fever which 
coincides with schizogony or erythrocytic rupture (Medscape, n.d.). The 
periodicity of the fevers, or malaria paroxysms, also depends on the particular 
species of the parasite. Tertian fever intermittently occurs every 48 hours due to 
P. falciparum, P. vivax, and P. ovale infection. Quartan fever intermittently occurs 
every 72 hours and is due to P. malariae infection. Usually, it is the patients with 
longer standing, constant malaria infections that present with this classic 
symptom. However, the periodicity of the intermittent fevers, is not reliable in 
malaria diagnosis. Considering there are numerous other illnesses and infections 
that cause reoccurring fevers, differential diagnosis is perhaps the cause of the 
inaccuracy of reported values of malaria morbidities and mortalities (Medscape, 
n.d.).  
The most aggressive of the malaria parasite species is the P. falciparum 
that is responsible for the most severe malaria cases as well as 90% of all 
malaria mortality (Snow & Omumbo, 2006). Malaria paroxysms for this particular 
strain rapidly escalate into severe disease complications such as cerebral 
malaria or severe anemia (“Impact Malaria” n.d.). Other complications of severe 
malaria affect the nervous, respiratory, renal, and hematopoietic systems 
(Trampuz, Jereb, Muzlovic, & Prabhu, 2003). The complications of severe 
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malaria usually occur between 3-7 days of fever onset. Thus, early and accurate 
diagnosis and treatment are extremely important for this particular infection. 
 
The Vector: 
The primary purpose of the female anopheles’ bite, or blood meal, is for 
the successful production of eggs. Blood meals, therefore, are important in the 
survival of the anopheles mosquito populations. Male anopheles never bite 
mammals as they lack a proboscis to piece the skin in order to take a blood 
meal. In consequence, they primarily feed on fruit and vegetable juices. The 
females have proboscis so they are able to select their mammalian hosts as 
some are zoophilic, preferring animals, and others are anthrophilic, preferring 
human blood. It is the anthrophilic female anopheles mosquitoes that are 
responsible for malaria transmission (Snow & Omumbo, 2006). Taking a look at 
the life stages of the anopheles, like all mosquitoes there are four stages of life. 
The first is the egg, then the larva, and then the pupa. These first three stages 
must take place in climate appropriate water (Tusting et al., 2013). Before 
reaching the adult stage, the water temperature and salinity is crucial to proper 
development. Standing water is ideal for almost all species of mosquitoes (CDC 
(a), n.d.). The anopholes larvae, in particular, are known to prefer water that is 
exposed to the sun (Urban Malaria Control Program, n.d.). Thus ideal breeding 
places for malarial mosquitoes include mangrove swamps, rice fields, grassy 
ditches, the edges of streams and rivers, sewages, and small, temporary rain 
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pools. Habitats with vegetation are also ideal (CDC (a), n.d.). The fourth and final 
stage of life is the adult stage that naturally lasts about 2 weeks. This is the 
mosquito’s reproductive stage as well as the period of time that it is capable of 
acting as a malaria vector. The adult female anopheles can lay up to 200 eggs 
directly on water. The eggs distinctively float on either side of the mosquito. The 
eggs hatch after 2-3 days and the cycle of life continues. In colder climates, this 
development process may take up to 3 weeks or even longer. It is important to 
note that the eggs are not resistant to drying (Tusting et al., 2013). Thus the 
aquatic or humid environment is important for its survival.  
The connection between the life cycle of the mosquito and the parasite is 
dependent on the life-span of the mosquito in its adult stage. The parasite 
completes its life cycle (gametocyte stage to sporozite stage) in the mosquito 
throughout a span of 10-18 days. If the mosquito, in its adult life lives long 
enough then it will be a successful vector. There are specific conditions to ensure 
successful development of the parasite. The most crucial conditions are 
temperature and humidity. Higher temperatures are known to accelerate parasite 
growth, increasing the likelihood of maturation within the mosquito lifespan (CDC 
(a), n.d.). Thus tropical climates, which are generally hot and humid, are ideal for 
both the parasite and the vector to thrive.  
Immune System: 
 The human immune system is critical for the protection of humans from 
malaria, in malaria immunopathology, and in the development of clinical immunity 
 5 
 
against malaria. Upon infection and as the result of an erythrocytic rupture, the 
presence of the parasites induce an immune response causing the release of 
cytokines which activate the hosts monocytes, neutrophils, T cells, and natural 
killer cells. These cells also respond to parasites in the liver and red blood cells. 
During hepatic infection, antigens brought along with the sporozite are presented 
on hepatocyte surfaces together with MHC (Major Histocompatibility Complex) 
Class I. The cytotoxic T lymphocytes recognize the antigens and kill the infected 
hepatocytes (Ho et al., 1986). Alternatively, natural killer cells and CD4+ T cells 
produce interferon gamma which causes an immune reaction cascade resulting 
in the death of an intracellular parasite. Thus, the parasite developing within the 
hepatocyte is a major target of protective immunity at the extra-erythrocytic stage 
(Perlmann & Troye-Blomberg, 2002).  
Malaria immunopathology has shown the role the immune system plays in 
disease progression. Early malaria research determined that tumor necrosis 
factor (TNF) is released upon malaria infection. There is also an increased rate of 
secretion of TNF during schizogony (Kwiatkowski et al., 1989). Studies also show 
that anti-TNF therapy inhibits the manifestation of fever in malaria (Kwiatkowski 
et al., 1993). TNF, is thus associated with the characteristic intermittent fevers. 
Fever is also caused by the parasitic invasion of macrophages and monocytes 
which also secrete TNF as well as other endogenous pyrogens. Pyrogens are 
also partially responsible for the characteristic fevers through their action on the 
hypothalamus causing an increase in body temperature (“Impact Malaria” n.d.). 
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The primary cause of the intermittent fevers, however, is the TNF as 
demonstrated by studies that show all the symptoms of malarial paroxysm by the 
injection of TNF into humans (“Impact Malaria” n.d.). The immune system, thus, 
has a role in the progression of disease. 
Protective immunity against malaria is acquired throughout life. In the first 
year of life, the newborn of an immune mother in a malaria endemic region has 
acquired immunity. This immunity is due to the passive transfer of IgG across the 
placenta, naturally protecting the newborn from infection (“Impact Malaria” n.d.). 
This protection, however, only lasts for the first 6 months of life. After these first 6 
months, the child then begins to build immunity as exposure to the disease is 
frequent, and the immune system responds appropriately (Artavanis-Tsakonas, 
Tongren, & Riley, 2003). By the time the child is of school age, greater than 6, 
the child then reaches clinical tolerance, or a stage of anti-disease immunity. The 
child may have high levels of parasitaemia but may only manifest mild malarial 
symptoms or may even be asymptomatic. Throughout the child’s life, if there is 
frequent re-infection and consistent or increased exposure, the child will 
eventually enter a state of premonition where there is significantly less 
parasitaemia and shorter episodes of infection (Artavanis-Tsakonas, Tongren, & 
Riley, 2003). This highlights the significance of a robust and active immune 
system not only in survival but in the development of sound immunity against 






Within populations, the burden of malaria is heaviest for certain groups 
who are vulnerable to infection, severe disease, and mortality. High risk groups 
include pregnant women, infants whose passive immunity has begun to wane, 
children under the age of five, HIV/AIDS (Human Immunodeficiency Virus / 
Acquired Immunodeficiency Syndrome) patients, and migrants or mobile 
populations whose immune systems are unfamiliar with the parasite (WHO (d)). 
For pregnant women, much of the complications arise from the 
immunocompromised state of pregnancy and the sequestering of infected red 
blood cells around the placenta. Although the parasites do not harm the fetus, 
babies born to infected mothers are more than twice likely to be underweight at 
birth (Schantz-Dunn & Nour, 2009). A majority of the malaria mortality befalls on 
children under the age of five, due to their underdeveloped state of immunity 
along with malnourishment and lack of medical attention. For migrants and 
mobile populations, the lack of immunity makes them highly susceptible to 
infection as many reach adult age without building protective immunity (CDC (b), 
n.d.).  
There is evidence that in regions of malaria and HIV infection, there is a 
debilitating interaction between the two. HIV infection, is known to suppress the 
immune system increasing the likelihood of malarial infection. HIV also increases 
the severity of malaria. As aforementioned, malaria increases CD4+ T cell 
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activation and increases the up-regulation of cytokines. This provides an ideal 
microenvironment for the HIV virus to spread among the CD4+ T cells and also 
for the rapid replication of the HIV virus (Alemu, Shiferaw, Addis, Mathewos, & 
Birhan, 2013). Therefore, malaria aggravates HIV and HIV increases the burden 
of malaria (“UNICEF,” n.d.). This is particularly important due to the heavy 
geographic co-infection of both diseases in Sub-Saharan Africa. Figure 1 shows 
regions of HIV prevalence indicated in darker colors. Most of the darkest shaded 
countries lie exclusively in sub-Saharan Africa similar to the regions in Malaria 
transmission as shown in Figure 2. 
 
Figure 1: Global Distribution of HIV infection 







High malaria prevalence is confined to sub-Saharan Africa. According to 
WHO’s World Malaria Report, in 2012 there were 97 countries still combating 
malaria transmission (WHO (d), n.d.). Of those 97 countries, a majority were in 
sub-Saharan Africa. Approximately 90% of malaria mortalities occur in sub-
Saharan Africa and 77% occur in children less than 5 years old (WHO(d), n.d.). 
This prevalence is consistent with the climate conditions. Considering the warmer 
and tropical regions are along the equator, malaria parasites thrive in these 
areas. Thus, transmission is more intense, and year-round (CDC (b), n.d.). The 
interesting thing to note about the distribution of malaria within the tropics is that 
prevalence is not as high in tropical regions of South America. Reasons for this 
disparity will be addressed in later chapters. However, as shown in the map in 





Figure 2: Global Distribution of Malaria 
Source: (CDC (e), n.d.) 
 
Malaria Burden 
For over a century malaria has been a global burden. Currently, this 
burden is perhaps the heaviest for Sub-Saharan African countries that bear the 
disease in addition to numerous other infectious disease and fragile economies. 
There are approximately 97 countries, most in Sub-Saharan Africa, that still have 
ongoing malaria transmission according to WHO’s 2013 World Malaria Report. In 
2012, there were about 207 million cases of malaria and about 627,000 
mortalities (WHO (d), n.d). The P. Falciparum parasite is responsible for almost 
all malaria mortality and it is estimated that the Sub-Saharan region bears about 
90% of its burden (Harrison, 1978). Thus the mortalities are mostly attributed to 
this particular strain of malarial parasite. It is important to note that these 
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numbers are estimates rather than approximations because of the 
incompleteness and inconsistency in diagnosis and assessments over time 
(WHO (d), n.d.). 
Although there has been much progress in vector control and in the 
eradication of malaria, there are still millions of people who suffer the burden of 
the disease at the expense of their lives. According to WHO, there are 219 
million new cases of malaria each year. Malaria is still a major public health 




Current Treatments and The History of Malaria 
 
The 19th and 20th centuries saw much discovery in the etiology and 
pathology of malaria as well as in malaria treatment. Although malaria treatment 
is determined by a myriad of factors, the most important is the species of malaria 
that caused infection and the part of the world in which the infection was 
acquired. These characteristics help in determining the extent of drug resistance 
and also in projecting the severity of disease (CDC (a), n.d.). Considering the 
prevalence of P. Falciparum in Sub-Saharan Africa, this species will be the focus 
of analysis in this chapter. 
 
Antimalarial Drugs 
As early as the 1600s, a quinolone containing substance, quinine, was 
extracted from the bark of a cinchona tree in South America and used in the 
treatment of fevers (Foley & Tilley, 1998; Sullivan, 2012). This symptomatic 
management long preceded the discovery of the malaria etiology and pathology 
by about 250 years. As a cinchona alkaloid, Quinine is basic so it is usually 
presented as a salt (Achan et al., 2011). Although the exact mechanism of action 
is unknown, research has identified that Quinine exerts its antimalarial effects 
primarily though the erythrocytic stage of infection. Targeting intra-erythrocytic 
malaria parasites, quinine is rapidly absorbed. Its chemistry, as a weak base, 
allows it to enter the food vacuole of the intra-erythrocytic parasite. Quinine then 
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works by inhibiting hemozoin bio-crystallization causing cytotoxic heme to 
accumulate, which is lethal to the parasite, inhibiting shizogony (Sullivan, 2012; 
Achan et al., 2011). Therefore, quinine is a schizonticide, because it is selectively 
destructive of the schizont of a parasite.  
The pharmacokinetics of quinine varies for the host and the severity of 
malaria. Quinine is rapidly absorbed orally as well as parentally. Binding to alpha-
1 acid glycoprotein, it is distributed within the body. Peak concentrations are 
reached between 1-3 hours. Through hepatic biotransformation, 80% is 
eliminated and the remaining 20% is excreted by the kidney. Its half-life is 11-18 
hours (Achan et al., 2011). For patients that are infected with malaria, high 
concentrations of alpha-1 acid glycoprotein causes increased binding to quinine 
which results in a decrease in quinine’s volume of distribution and a decrease in 
elimination time (Achan et al., 2011). Therefore, malaria patients generally 
sustain high levels of quinine. Due to its low therapeutic index, physiological 
dangers of its use are referred to as cinchoism. This includes headache, nausea, 
hearing impairment, vomiting, and diarrhea (Sullivan, 2012). Despite its negative 
side effects, quinine was the most widely used and the only thoroughly effective 
anti-malarial treatment in its time. By the 1920s, other synthetic anti-malarial 
drugs became available and most were more effective with less severe side 
effects. By World War II, research produced a myriad of drugs that almost 
replaced quinine (Encyclopedia Britannica, n.d.). Perhaps the most notable is the 
drug chloroquine which was extremely widely used by the 1940s (Achan et al., 
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2011). Investigators of six countries worked on chloroquine from 1934 to 1946 
from initial discovery, rejection, re-discovery, evaluation and finally its acceptance 
in 1946. By the 1950s and 1960s, chloroquine was the main antimalarial drug 
choice for WHOs Global Eradication Programme for malaria (Meshnick, 2002). 
Chloroquine is also a weak base and a quinolone, synthesized to mimic 
the schizonticidal effects of quinine. Thus, its mechanism of action is the same. 
Chloroquine was shown to be more effective than quinine in slowing parasite 
growth (Encyclopedia Britannica, n.d.). Moreover, its wider therapeutic index 
made it safer to use than (Achan et al., 2011). Chloroquine achieved much 
success worldwide that in the 1950s, a Brazilian named Marco Pinotti introduced 
an idea of inserting the drug into cooking salt. The idea was well accepted and 
employed in South America, Asia, and Africa. Beginning in the 1960s, 
chloroquine use was halted due to increased cases of parasite resistance to the 
drug (Meshnick, 2002). Chloroquine’s acceptance, wide-spread and heavy use 
marked the beginning of malarial drug resistance. By the 1980s, most areas with 
P. falciparum malaria saw chloroquine resistance. This then brought quinine back 
to the forefront of antimalarial drugs, as the parasite still remained sensitive to it 
(Achan et al., 2011).  
By definition, antimalarial drug resistance is the ability of the parasite to 
survive and continue to multiply despite drug administration of doses equal and 
higher of that recommended within tolerance of the subject (Bloland, P., 2001). 
P. falciparum resistance to chloroquine is due to the parasite’s ability to expel 
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chloroquine from its food vacuole fast enough before it exerts its schizonticidal 
effects. So before chloroquine can reach levels of heme polymerization, it is 
removed from the parasites food vacuole resulting in a decrease in the 
schizonticidal effects (Bloland, P., 2001). Chloroquine efflux can occur at a rate 
40 to 50 times faster among parasites that are resistant compared to those that 
are not (Krogstad et al., 1987). This mechanism of resistance was verified with 
drugs such as verapamil that reversed the action of the efflux system, allowing 
chloroquine to accumulate and exert its effects (Martin, Oduola, & Milhous, 
1987). Presently, the P. falciparum species has developed resistance to almost 
all antimalarial drugs, only varying in geographical distribution of the resistance 
(Bloland, P., 2001). In all regions of high P. falciparum infections, resistance to all 
antimalarial drugs has developed (CDC (a), n.d.). This evolution of resistance 
against affordable drugs, such as chloroquine, causes a tremendous societal and 
economic cost in combating malaria.  
 
 Artemisinin Drugs and Political Involvement: 
For almost 2,000 years, Chinese herbal medicine practitioners have been 
using Artemisia annua to treat hemorrhoids. The history of the drug Artemisinin 
began in the Cultural Revolution in China in efforts to assist North Vietnam in the 
war against the United States. P. falciparum malaria was a burden to the 
Chinese Army and by this time, the parasite had already developed resistance to 
chloroquine. Vietnam then turned to China for help. This began Project 523 
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which was coded for the first meeting in 1967 to discuss the problem of 
chloroquine-resistant P. falciparum. By 1972, the active ingredient of Artemisia 
annua, Qinghaosu, was purified (Meshnick and Dobson, 2011). Concurrently with 
the Cultural Revolution occurring in China came clinical trials that showed 
Qinghaosu to be effective in rapid clearance of malarial symptoms, primarily 
parasites and fevers (Tu, 2011). As the research was a military secret, results 
and findings of the efficacy of Qinghaosu were not shared with the outside world 
before the revolution. After the revolution, results were published in the late 
1970s and early 1980s (Meshnick and Dobson, 2011). In October 1981, a WHO 
Chemotherapy of Malaria group visited Beijing and Professor Youyou Tu 
presented the work of Project 523 (Miller & Su, 2011). Shortly after, a publication 
of the description of Artemisinin was made available. This information revealed 
artemisinin’s structure as a sesquiterpene lactone with an endoperoxide. The 
endoperoxide was revealed to be responsible for its antimalarial activity. 
Unfortunately, although the chemistry of the substance was available, the 
Chinese scientists wouldn’t share the method of crystallization and purification of 
the substance from the plant (Milhous & Weina, 2010). Arnold, a malaria 
researcher with the Walter Reed Army Institute, went to Hong Kong in 1979 to 
test the Army’s newly developed drug mefloquine, another antimalarial. After 
trying out his drug against artemisinin, it was clear that artemisinin was a front-
runner in malarial treatment and this brought much attention to the Chinese drug 
(New York Times (a)). WHO took notice but political hesitation from both China 
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and the West resulted in no action. In 1984, Klayman, also with the Walter Reed 
Army Institute of Research in the United States, determined that Artemisinin 
Annua, in same structure, could be isolated from sweet wormwood, which grew 
along the shores of the Potomac River (Klayman et al., 1984). Unfortunately, 
Klayman’s compound, in drug form, was found to not be as effective as the 
Qinghaosu extracted by the Chinese.  
Shown to be highly effective, artemisinin wasn’t used in regions of dire 
need due to political conflict. Aid agencies were unable to buy drugs that were 
not endorsed by WHO. By the 1990s, the international conflicts stalled efforts to 
collaborate with China to get artemisinin into the drug market. Dr. Arnold called 
WHO’s indecisiveness “genocidal” as nearly 1 million children in sub-Saharan 
Africa died from malaria while political dissention continued. In 2000, WHO finally 
endorsed artemisinin although it wasn’t available until 2006. Before its 
availability, in 2002 the Médecins Sans Frontières (MSF) demanded access to 
artemisinin but an adviser to the US Agency for International Development, 
Dennis Caroll, claimed that it “was not ready for prime time” (New York Times 
(b), n.d.). The political discord muddled the health efforts delaying endorsement, 
distribution, and usage. Chloroquine and other cheap drugs continued to be used 
despite the wide-spread resistance. 
In China, patent law disappeared under communism. Western patents 
were not removed so major drug companies were unable to monopolize and 
profit from artemisinin. In 1994, a neutral, Swiss company, Novartis, bought a 
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new patent on a mix of artemether, which is an artemisinin derivative, and 
another Chinese drug, lumefantrine (New York Times (b), n.d.). Novartis planned 
to sell the mix under the name Riamet to militaries and tourists at a very high 
price tag but in 2001 agreed to sell it to WHO under the name Coartem. Coartem 
was sold at a price of $1.57 per treatment but much lower for children who were 
most vulnerable to malaria’s morbidity and mortality (Lefèvre, Marrast, & 
Grueninger, 2011). The price was still relatively expensive for many of the 
populations in Sub-Saharan Africa. It wasn’t until the creation of the Global Fund 
to Fight AIDS, Tuberculosis and Malaria in 2002 and President Bush’s 
Administrations President’s Malaria Initiative in 2005 that the drug became 
available to populations in developing countries.  
These organizations bought out the drugs to deliver them to the world’s 
most endemic regions. Created in 2005, President’s Malaria Initiative, sought to 
expand government resources of $1.2 billion to reduce the intolerable burden of 
malaria and help relieve poverty on the African continent. The four strategies 
used include insecticide-treated mosquito nets (ITNs), indoor residual spraying 
(IRS), intermittent preventive treatment for pregnant women (IPTp), and 
artemisinin-based combination therapies (ACTs) (Presidents Malaria Initiative 
(PMI), n.d.). Provision of Novartis was a part of the deal. In 2002, The Global 
Fund to Fight AIDS, Tuberculosis and Malaria was founded to increase 
resources for the fight against malaria, tuberculosis, and AIDS. By creating and 
spurring partnerships between government, civil society, the private sector and 
 19 
 
communities living with the diseases, the Global Fund drives remarkable 
progress in alleviating the burden of all three diseases in sub-Saharan Africa. For 
malaria, the Global Fund funds approximately 50% of all international funding to 
support the anti-disease efforts in prevention and eradication (Global Fund (a)).  
Therefore, these organizations were pivotal in the availability of antimalarial 
drugs in the world’s most endemic regions.  
The highly effective and controversial artemisinin is a sesquiterpene 
lactone bearing a peroxide grouping. Different from other antimalarials, it lacks a 
nitrogen-containing heterocyclic ring system (Klayman et al., 1984). The 
mechanism of action involves the heme-mediated decomposition of the 
Endoperoxide Bridge producing carbon centered free radicals (Meshnick, 2002). 
Its selectivity to heme explains why it is toxic to malaria parasites. The exact 
mechanism of action is still under research however studies have shown, for 
example, that artemisinins directly impair mitochondrial functions of the malaria 
parasite (Vijverberg & vanden Bercken, 1990).  
Comparative studies looking at the efficacy of artemisinin and mefloquine 
spurred suggestions that a combination therapy would prevent re-occurrence of 
malarial symptoms as well as the development of resistance. Mefloquine was 
found to work more slowly than artemisinin in parasite clearance. Artemisinin’s 
very short half-life requires use of a slow clearance antimalarial to prevent 
reoccurrence (Li, Arnold, Guo, Jian, & Fu, 1984). There was a growing fear in 
endemic regions of China that parasite resistance to artemisinin would arise as 
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many patients who took the drug as a standalone wouldn’t continue treatment 
after symptoms were cleared. Ultimately, they were not cured, and incomplete 
treatment would mark the beginning of drug resistance (Li, Arnold, Guo, Jian, & 
Fu, 1984). In later years, White, working in Thailand, confirmed artemisinin’s 
rapid activity and the need for a partner drug to effectively clear the malarial 
parasite(New York Times (a), n.d.). This then became the centerpiece of the use 
of artemisinin derivatives in combination therapy.  
Artemisinin-based combination therapy is currently recommended for P. 
falciparum treatment. Fast acting Artemisinin compounds and derivatives such as 
Dihydroartemisinin, Artesunate and Artemether are used in combination with 
slower acting drugs such as Lumefantrine, Mefloquine, Amodiaquine, 
Sulfadoxine/Pyrimethamine, Piperaquine and Chlorproguanil/Dapsone (Malaria 
Consortium, n.d.). According to the CDC, P. falciparum has also developed 
resistance to drugs such as Quinine, Mefloquine, Halofantrine, and Sulfadoxine. 
The resistance to these drugs is less widespread. Currently, there have been an 
increase in the number of cases of decreased efficacy of ACT treatments in 
Southeast Asia (Dondorp et al., 2009; Meshnick, 2002). One of the greatest 
challenges in the next few years will be to maintain efficacy of these top line 
treatments by preventing resistance. This will require thorough drug monitoring 
as well as patient compliance.  
 
Public Health Interventions: 
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Non-clinical malaria interventions are targeted to preventing the infectious 
bite of the mosquito, thereby reducing transmission. One of the most heavily 
funded preventative measures is Insecticide Treated Nets (ITNs). According to 
the CDC, ITNs reduce the malaria mortality of children by 20% (CDC (d), n.d.). 
Treated with pyrethroid insecticide, ITNs are bed nets forming a protective barrier 
around people sleeping under them. The insecticide repels and kills mosquitoes 
as well as other insects. By acting on the insect’s nervous system’s voltage gated 
sodium channels, pyrethroid causes prolonged membrane depolarization and 
enhanced neurotransmitter release. This is followed by a block of excitation 
leading to eventual death (Vijverberg & vanden Bercken, 1990). In a study 
assessing the impact of pyrethroid-treated bed nets among children and adults 
living in malaria endemic regions, pyrethroid treated nets or curtains were shown 
to decrease malaria mortality, severity, parasitaemia, anemia, and spleen rates 
(Lengeler, 1996). The pyrethroid insecticide has shown to pose a low risk for 
humans and mammals but is very toxic to insects even at low doses. Therefore, 
pyrethroid has high potency and selectivity for insects. Part of the reason for this 
selectivity is the fact that pyrethroid depends on negative temperatures to exert 
its action, which is impossible within the mammalian body. Nevertheless, 
independent of temperature, mammalian sodium channels have demonstrated to 
be at least 1000 times less sensitive to pyrethroids in comparison to insect 
counterparts (Vais, Williamson, Devonshire, & Usherwood, 2001). Thus, 
pyrethroid is widely accepted for use in bed nets. If washed or exposed to 
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sunlight, pyrethroid can break down and devoid the bed nets of the protective 
effects. As a result, bed nets must be retreated every 6-12 months with the same 
insecticide (CDC (e), n.d.).  This need for re-treatment poses an additional cost 
for maintenance. On the other hand, the lack of re-treatment poses a risk of the 
development of pyrethroid resistance. In order to manage resistance some 
companies began to include piperonyl butoxide (PBO) along with pyrethroid in 
ITNs. WHO, however, does not consider PBO treated nets as a tools to manage 
rising pyrethroid (CDC (e), n.d.). A limitation of pyrethroid treated bed nets is also 
resistance. The first reported case of pyrethroid resistance was in Cote d’Ivore in 
1993 and has spread to almost all regions in Sub-Saharan Africa with the 
exception of Southern Africa (Ranson et al., 2011; Corbel et al., 2007; 
Santolamazza et al., 2008; Abdalla et al., 2008).  
Recently, a number of companies have developed Long-Lasting 
Insecticide-treated Nets (LLINs). These nets are capable of withstanding washing 
and sunlight for up to 3 years.  From 2008 to 2010, 294 million LLIN nets were 
distributed in sub-Saharan Africa. WHO has currently approved or given interim 
approval to the use of 13 LLINs (WHO (a), n.d.) LLINs are distinct from other 
ITNs in that they are made with a netting material that includes insecticide within 
and around the material fibers. The standard ITNs are treated simply by dipping 
into insecticides so this new concept removes the need for nets to be retreated 
annually (Malaria Consortium (b), n.d.). Insecticides used in this method include 
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Deltamethrin, PBO, polyethylenes, Alpha-cypermethrin, and many others in 
combination or as standalone treatments (WHO (a), n.d.). 
Another non-clinical method of malaria prevention includes Indoor 
Residual Spraying (IRS). This method involves spraying or coating walls of a 
house with a residual insecticide such as dichloro-diphenyl-trichloroethane, also 
known as DDT, indirectly preventing the mosquito bite, the insecticide kills the 
mosquitoes after a blood meal when they usually rest in an indoor surface (CDC 
(a), n.d.). This is when the parasite develops and matures within the mosquito 
enabling transmission. Thus the goal of IRS is to prevent malaria by killing the 
mosquito before it bites another host, reducing transmission. 
The history behind IRS began in 1946. During the Global Malaria 
Eradication Campaign from 1955-1969, IRS and Chloroquine were the main 
malaria control interventions (Africa Indoor Residual Spraying Program, n.d.). 
The campaign unfortunately did not reach its intended objective however it did 
eliminate malaria from some endemic areas, reducing the burden of the disease 
(CDC (d), n.d.). In 1962, following Rachel Carson’s book Silent Spring, 
environmental concerns as well as increased DDT resistance of mosquitoes 
caused the campaign to end (Africa Indoor Residual Spraying Program, n.d.). 
DDT environmental concerns also led to the introduction of more synthetic 
insecticides. As many of the endemic countries could not bear the financial 
burden of purchasing DDT, the campaign collapsed (Africa Indoor Residual 
Spraying Program, n.d.; CDC (f), n.d.). IRS programs were consequently 
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disbanded. In South Africa, DDT was replaced with alternative chemicals for IRS. 
The region then saw an increase in malaria mortality and DDT was quickly re-
employed (Bouwman, van den Berg, & Kylin, 2011). Recent success in reducing 
malaria mortality in South Africa revived interests in IRS (CDC (d), n.d.). IRS 
DDT programs were consequentially re-introduced to Sub-Saharan Africa. 
According to WHO, DDT has long lasting efficacy of more than 6 months, making 
it a good candidate for sustained use as IRS (WHO (a), n.d.).  If resistance is to 
be avoided in the long run, use and maintenance must be consistent and well 
monitored.  
Vulnerable groups to malaria are very sensitive to transmission. Proper 
interventions must be tailored for these preventative efforts to be effective. In 
addition to ITNs, LLINs, and IRS, pregnant women, especially those living in high 
transmission areas, are recommended to take Intermittent Preventive Treatment 
(IPTp). IPTp encompasses administration of an antimalarial, regardless of the 
presence of infection, during each antenatal care visit (Greenwood, 2006). The 
antimalarial is Sulfadoxine-Pyrimethamine. This differs from standard 
chemoprophylaxis in that it produces protective drug concentrations for short 
periods of time separated by periods of concentrations below that necessary to 
inhibit parasite growth (Kayentao et al., 2005). Currently, it is the only antimalarial 
for which there is clinical efficacy and safety data for IPTp (Peters, Thigpen, 
Parise, & Newman, 2007). WHO recommends that two doses of Sulfadoxine-
Pyrimethamine should be given during the antenatal visits and should begin 
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during the second trimester (WHO (b), n.d.). Additional studies of Sulfadoxine-
Pyrimethamine has shown efficacy in preventing placental accumulation of 
parasites among pregnant women in Kenya (Parise et al., 1998). In addition, a 
study of Mozambican infants showed that intermittent Sulfadoxine-
Pyrimethamine treatment reduced the incidence of clinical malaria by 22.2% 
(Macete et al., 2006). Although not an overwhelming percentage, this reduction is 
useful. WHO recommends that Intermittent Preventive Treatment (IPTp) is 
administered 3 times within an infant’s first year of life (WHO (c), n.d.). This 
intervention, however, is only helpful for women and infants who have sustained 
means of accessing healthcare. 
 
The Vaccine 
With many problematic and failed efforts, the malaria community is now 
focusing on a new vaccine currently being developed by companies 
GlaxoSmithKline and PATH. Beginning in the 1980s, the vaccine has undergone 
changes and modifications and is finally in the phase 3 clinical trial stage which 
began in various African Countries in 2009 (Vekemans, Leach, & Cohen, 2009). 
The Vaccine, RTS,S ASO1, is developed as a hybrid antigen containing the 
HepB surface antigen and the sporozite protein antigen. It also includes an 
adjuvant, AS01, which acts as an immunostimulant. The biological rationale for 
this vaccine is that it elicits a strong humoral response directed against the 
sporozite before it enters and infects the red blood cells, via opsonization or 
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macrophage destruction (PATH Malaria Vaccine Initiative, n.d.).  Moreover, 
because the sporozites are in the blood stream for less than 30 minutes (some 
enter the liver cells and remain dormant), the vaccine must also be effective in 
combating infected liver cells. The hybrid antigen plays a role in eliciting cell 
mediated immune response via CD8+ and CD4T cells to recognize parasite 
peptides that are expressed on infected liver cells. T lymphocytes then lyse 
infected cells (PATH Malaria Vaccine Initiative, n.d.). Much of the success in the 
preclinical and clinical stages has set up high expectations for this vaccine. 
Phase 3 clinical studies in various African countries show that the vaccine 
confers some protection against severe malaria among infants and children. In 
one of the trials, the RTS,S/AS01 vaccine co-administered with EPI vaccines, 
showed to provide some protection against clinical and severe malaria in young 
infants. Infants were 6-12 weeks of age and the vaccine showed efficacy in 
protecting against malaria in 31.3% of the infants, efficacy against severe malaria 
in 26.0%, and 99.7% of the all infants who received the vaccine were positive for 
anti-circumsporozoite antibodies (Agnandji et al., 2012). Perhaps the low 
numbers in protective efficacy are due to the fact that infants already have 
passive immunity conferred from their mothers in the first 6 months of life. In a 
similar study among children 5-17 months of age, vaccine efficacy against 
malaria was 50.4% and efficacy against severe malaria was 45.1%. Data also 
shows that three doses of the vaccine provided partial protection 18 months after 
inoculation however the efficacy appears to decrease over time (Agnandji et al., 
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2011). Considering that the vaccine is now in the last phase of clinical trials 
before it is marketed, these results indicate partial and insubstantial efficacy that 
may cost more to develop and obtain than it assuages the burden of the disease. 
Although this vaccine has shown some efficacy, it is important to note that its 
long term efficacy has yet to be evaluated.  
Currently, there hasn’t been a successful vaccine against parasitic 
infection. There have been many successful vaccines against worldwide 
pandemics such as polio however the life cycle of the parasite and the complex 
etiology and pathology of malaria makes finding an effective vaccine 
complicated. One of the reasons is that the parasites are genetically and 
biologically complex. Their life cycles are elaborate and can quickly master 
immune system evasion (Tarleton, 2005). In a recent article, the authors also 
contend that the complex life cycle and the parasite’s ability to evade host 
immune response is one of the major challenges preventing a successful 
vaccine. The author contends that a vaccine that enables complete resistance to 
infection is probably not feasible however attention should be directed to create 
an antitoxic vaccine that prevents the pathological complications of malaria 
(Playfair, Taverne, Bate, & Brian de Souza, 1990). Given the ability of the 
parasite to evade and evolve, one of the most difficult challenges will be ensuring 
that increased parasitic virulence does not ensue. A recent study points out that 
partially effective vaccines, such as those for malaria, may do more harm than 
good. In this study, the impact of various partially effective vaccines was 
 28 
 
assessed in relation to pathogen virulence marked by host mortality. Evidence 
from the study proves that partially effective vaccines languish the natural 
selection against highly virulent pathogens. This results in a more severe form of 
the disease in those individuals whom are not vaccinated (Gandon et al., 2001). 
This information is extremely vital in dealing with a case such as malaria where 
previous interventions have been imperfect and not thorough in coverage due to 
problems beyond that of the actual disease. Even more so, it is important 
considering the fact that virtually all interventions have seen resistance.   
 
Parasite and Vector 
Although the parasite is highly virulent and fatal to humans, it seems to 
have little to no effect on the mosquito vector. It is unknown how the relationship 
between the parasite and the mosquito evolved. Recent studies have attempted 
to elucidate this relationship showing that the parasite does have some effect on 
the behavior of the mosquito. In a recent study by Smallengange et al. (2013), P. 
Falciparum infected Anopholes Gambiae (main mosquito species carrying the P. 
Falciparum parasite), were more attracted to human odors than non-infected 
mosquitoes. In this blind study, when the mosquitoes were exposed to a sock 
emanating human odor, significantly more of the infected mosquitoes landed on 
the substrate. Smallengange et al (2013) suggest that this demonstrates a 
change in the mosquito’s response to olfactory stimuli when infected with the 
parasite (Smallegange et al., 2013). This means that infected mosquitoes are 
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more likely to bite a human host increasing the chance of transmission. It is 
important to note that this behavior suggested by literature is more detrimental to 
humans than to the mosquito. As most interventions focus on controlling the 
disease by killing the mosquito, new survival mechanisms evolve as seen with 
increased resistance to almost all drug and insecticide interventions as 
aforementioned. A recent study on the M and S forms of the Anopholes Gambiae 
found that the two have diverged in larval ecology as well as in reproductive 
behaviors. These changes are through unknown genetic mechanisms that 
suggest a speciation process taking place (Lawniczak et al., 2010). The P. 
Falciparum parasite is also undergoing genetic changes as demonstrated by 
Jeffares et.al (2006). In the study, genetic variation and mutation is clearly 
demonstrated within the parasite and its species. Thus, both the parasite and the 
vector are rapidly evolving to be better suited for survival. Interventions must re-
focus on means to eradicate the disease once it has entered the human body, as 
other external interventions seem to aggravate the problem by spurring natural 
selection. 
 
History of Malaria 
In order to create new and effective means of controlling and eradicating 
malaria, it is important to assess the history to understand how to best move 
forward. Although discovery took place within the past 200 years, malaria 
symptoms were recorded as early as 2700 BC in China in the Nei Ching, which 
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was the Canon of Medicine. By the second century BCE, the Qinghao plant, was 
used in treating the symptoms (CDC (b), n.d.). In 340 CE, its anti-fever properties 
were discovered and recorded. Today, the plants active ingredient, Qinghaosu, is 
used in antimalarial drugs.  In Greece, around the fourth century, malaria was 
recognized as the cause in the decline of populations. Hippocrates was 
responsible for noting the main symptoms of it (CDC (b), n.d.).  
The discovery of malaria etiology and pathology began with colonialism 
and war. During the scramble for Africa, the battle against malaria began as 
colonials, armies, and settlers began suffering from symptoms (Harrison, 1978). 
Mortality rates rose warranting investigation on the identification and cause of the 
disease. In 1880, a French army surgeon, Charles Laveran, living in Algeria 
discovered parasites in the blood of a patient who suffered from malaria. 
Laveran, however, did not arrive to this conclusion on his own. A forerunner of 
Laveran, Achille Kelsh, noted that in patients who died of malaria, there were 
small, black particles in certain organs that eventually lead to their discoloration 
(Harrison, 1978). Speculation the causative substance continued until Laveran’s 
discovery. What made Laveran’s discovery significant was his keen observance 
in asking the right questions. Laveran sought to identify what happens in malaria 
that doesn’t happen in any other disease. After observing fresh blood, he 
discovered motile elements, which were the protozoan parasite, as the cause of 
malaria (CDC (b), n.d.; Harrison, 1978). Like many other discoveries, Laveran’s 
parasite was met with much skepticism as many continued to insist on a bacterial 
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cause. By 1890, Laveran’s parasite was accepted as the cause of malaria. In 
1886, Golgi, an Italian neurophysiologist, discovered that there were 2 forms of 
the disease, distinguishing between tertian and quarternary fever (CDC (b), n.d.). 
In his observation, he found that the forms had differing numbers of merozoites 
produced upon maturity. Golgi also observed that the intermittent fevers 
coincided with the rupture of erythrocytes and the release of merozoites, or 
schizogony. In 1890, Grassi and Filetti, also Italians, introduced the names P. 
vivax and P. malariae for two of the malaria parasites that affect humans. In 
1897, Welch named a tertian parasite P. falciparum, and in in 1922, Stephens 
named the fourth human malaria parasite P. ovale (CDC (b), n.d.). 
During the 1870s in China, while studying elephantitis, Manson 
demonstrated that mosquitoes might be vectors of disease. He discovered that 
the filariae that cause elephantitis mature in mosquitoes. However, his curiosity 
didn’t quite peer into how infection takes place (Harrison, 1978). He did, 
however, pave the way for discovery of mosquitoes as vectors of disease. In 
1897, a British officer, by the name of Ronald Ross who working for the Indian 
Medical Service, demonstrated that mosquitoes are responsible for transmitting 
the malaria parasites among infected patients (CDC (b), n.d.). In efforts to prove 
the hypothesis of Laveran and Manson connecting the mosquitoes and malaria, 
Ross closely recorded his work investigating the role the mosquito plays in 
infection. Finally, in August 20th 1897, Ross discovered the malaria parasite in 
the stomach tissue of a female anopholes mosquito that fed on a malarious 
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patient (Harrison, 1978). Ross also further proved his finding in July of 1898 
when he showed that mosquitoes were responsible for transmitting the malarious 
parasite among birds. Ross’ observation also revealed that parasites, once 
developed in the mosquito, migrate to the insects’ salivary glands linking parasite 
transmission to the mosquito (CDC (b), n.d.; Harrison, 1978). 
Perhaps the most important aspect of malaria history is the history of its 
epidemiology and interventions. As the scramble for Africa led to term many 
regions “the White Man’s grave”, yellow fever and malaria began to take a toll on 
political and economic interests in these heavily endemic regions. In the year 
following his discovery, Ronald Ross initiated the first anti-larval measures to 
control malaria in Freetown, Sierra Leone (Bockarie, Gbakima, & Barnish, 1999). 
In 1901, Sierra Leone was also battling yellow fever whose vector was also 
known to be a species of mosquito, Aedes Aegypti. So after Ross discovered the 
mosquito as the vector, he also speculated that it picked up the parasite germ 
from puddles where they feed. He concluded that the puddles had to be 
eliminated as a means of eliminating mosquitoes. In 1901, 70 employees led by 
Ross, began anti-larval efforts by cleaning the pestilential parts of Freetown, 
Sierra Leone (Harrison, 1978). The city organized removal of garbage, began to 
sweep, drain, and oil puddled streets and yards. Unfortunately, the cleanup was 
not maintained after Ross left Freetown and all efforts were abandoned (CDC 
(b), n.d.; Harrison, 1978)..  
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Anti-larval efforts were also attempted during the construction of the 
Panama Canal from 1905-1910. The hot, wet climate of Panama saw about 85-
90% of 26,000 workers hospitalized for yellow fever and malaria (PBS, n.d.). 
Yellow fever was particularly gruesome as death rates were extremely higher 
than malaria. Early symptoms were headaches, fever, and myalgia and 
progression of the disease eventually led to a dark, bloody vomit indicative of 
internal bleeding. The end result was organ failure and death. Malaria, although 
not as disastrous, caused relapse and recrudescence resulting in frequent and 
expensive hospital stays (Harrison, 1978). The symptoms of both diseases are 
similar although the pathophysiology of yellow fever is very different. The high 
fatality rates were mortifying enough to send workers fleeing from the site, 
abandoning the building of the canal. At the time, the only treatment widely 
accepted and available was quinine. It was given to assuage the fevers but that 
didn’t decrease the mortality rates. Moreover, high doses caused cinchoism 
among many (CDC (b), n.d.; Harrison, 1978). 
Through the leadership of physician, William Crawford Gorgas in Panama, 
launched one of the largest sanitary campaigns in malaria history. In 1905, 
fumigators with cleaning agents, insecticides, and protective screens visited 
private homes in Panama. They sprayed drains and cesspools, with oil (Harrison, 
1978; PBS, n.d.). The resources to carry out this order were not cheap and 
required substantial funding and government support to carry out. Political 
pressure to complete the canal, as reported by PBS, finally pushed President 
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Roosevelt to back Gorgas’ efforts (PBS, n.d.). In 1912, the antilarval clean-up led 
to a victory in Panama as the number of hospitalized workers fell to 5,600 (CDC, 
(b), n.d.) Cases of yellow fever were easier to decrease however, malaria would 
take much longer to eliminate. The burden of disease was relieved and the canal 
was complete. Panama serves as an example of effective malaria control with 
government support and integration in alleviating the burden of disease.  
In Italy, Malaria was an endemic disease with cases up to 2 million 
towards the end of the 19th century. Tertian malaria was endemic in central and 
southern regions of Italy as well as the Islands (Majori, 2012). Dr. Angelo Celli, 
an intellectual historian, saw malaria as a social problem. He believed that fever 
was a cause and result of the impoverished lifestyles of those in the central and 
southern provinces. Moreover, Celli believed that the war on malaria would best 
be fought by the defending people rather than fighting against mosquito 
populations (Harrison, 1978). However, as mosquito control at that time proved 
to formidably be successful and reform seemed too long term of an action to be 
taken, Celli concluded that quinine was the best antimalarial treatment at hand 
(Harrison, 1978). The early Antimalarial campaign in Italy focused on therapeutic 
quinine. It was made widely available, free of charge, and the government 
ensured supplies were widely distributed especially among the more endemic 
regions.  Moreover, the parliament approved laws to promote measures aiming 
to reduce larval breeding places of vectors in draining and oiling methods as 
previously mentioned (Majori, 2012). Although it began as a campaign against 
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malaria, lack of literacy and adherence to the program among endemic 
populations resulted in a social melioration. Malaria morbidity did, however, fall to 
a low of about 2,000 in 1914 before the beginning of World War I (Harrison, 
1978).  
The role of the Great War (World War I) in malaria history highlighted the 
inadequacies of current treatments. During the war, many war zones became 
encouraging or permissive to malaria epidemics as infected soldiers recruited for 
war were introduced to a region capable of housing the disease. Non-immune 
soldiers were consequently infected with the disease. When the Great War 
ended and soldiers returned to their homes, they in turn introduced the disease 
to a region that was capable of housing it, and the disease spread in regions that 
were previously non-malarious. From 1914-1918, the only effective drug used 
was Quinine. However, its limitations laid in its unwanted side-effects, crippling 
military efforts during a crucial time. Malaria control measures were employed 
such as drainage schemes to eliminate the mosquito breeding places, use of bed 
nets, and application of insecticides (CDC (b), n.d.). The German army served as 
an example of how the use of malaria immune troops, good hygiene, and 
appropriate medication makes a difference between success and failure 
(Gachelin & Opinel, 2011). Nevertheless, antimalarial work was back to the 
starting point as non-endemic regions saw increased malarial infection.  
The Great War highlighted the need for access to quinine and more 
comprehensive preventative methods for malaria. By the time World War II 
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began, there was a need to develop new antimalarial drugs. Germany, Great 
Britain, and America, by their engagement in the war and by suffering the 
morbidity and mortality of malaria, were the main countries involved in the 
development of synthetic antimalarials (Schlaugenhauf, Patricia, 2004). Some of 
the antimalarial drugs synthesized were DDT, Chloroquine, and Abatrine (Hays, 
2000). These new tools brought back optimism in fighting malaria and led to 
developments of numerous organizations and campaigns in the post-war years. 
DDT proved to be successful and the newly synthesized antimalarial drugs 
proved to be less toxic and more effective than quinine. In 1955, WHO proposed 
a program to eradicate malaria worldwide with the newly discovered drugs. The 
efforts began and focused on IRS, antimalarial drug treatment, surveillance and 
maintenance (CDC (d), n.d.). Some highly endemic, colonized nations saw 
significant reduction such as India and Sri Lanka. Other nations, mostly in Sub-
Saharan Africa, were completely excluded from the eradication campaign. The 
main reasons were attributed to challenges of executing the eradication methods 
and strategies within the region (WHO (a), n.d.). Globally, the emergence of drug 
resistance to antimalarial drugs and insecticides began making the maintenance 
untenable. Efforts in the regions ceased and malaria made a resurgence (CDC 
(f), n.d.). In other non-endemic regions malaria cases waned and the regions 
eventually became malaria free. One such is the United States. 
Taking a comprehensive look at Malaria in the United States, malaria 
cases were observed as early as the 1800s long before the discoveries of Ross 
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and Laveran. Before the turn of the century, malaria developed to a climax and 
diminished. Due to climate, southern regions were highly malarious and the north 
was only malarious during the warmer months when the parasite and mosquito 
could thrive. Decline in malaria was seen around the 1860s however the civil war 
caused an increase in morbidity and mortality (Faust, 1951). It was in the 1920s 
that malaria efforts began in the United States. Between 1900 and 1920s, 
malaria declined as a result of efforts such as those utilized by Gorgas, 
particularly that of drainage. Although record keeping wasn’t extensive, records 
show that there was a peak in malaria cases between 1933 and 1936, 
presumable as a result of the economic depression that halted eradication 
efforts. Nevertheless, within the 20th century malaria became virtually extinct in 
the United States. Factors contributing to this include improvement in agriculture 
and improvement in drainage eliminating breeding grounds for the mosquito. The 
life cycle of the parasite waned and fewer mosquitoes picked up the parasite. 
Over time, this translated into fewer infections and a decline in cases. Even 
before the Great War, malaria control was successful through public health, 
economic, and sociologic programs. Better housing, better screening, availability 
and extensive use of insecticides resulted in improvement of the population 
health (Faust, 1951). The Southern States still witnessed malaria, however. So 
during WWII, when Northern soldiers were being trained in the malarious south, 
and as many returned home from endemic regions throughout the world, malaria 
cases increased. On July 1, 1947, the National Malaria Eradication Program 
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began work. DDT application of all homes and premises of malarious regions 
was ordered. By 1949, about 4.6 million homes had been sprayed. Drainage, and 
other methods of removing the breeding site of larva were also ordered and 
eradication looked close (Faust, 1951). In 1949, malaria was no longer a public 
health problem in the United States, and by 1952, CDC participation within the 
country ceased (CDC (a), n.d.).  Even in the face of relapse, the US no longer 
saw an epidemic. Most cases of malaria today are usually the result of travelers 
coming in from malarious regions. Nevertheless, the eradication of malaria in the 
US shows how efforts can be successful wherein multi-sectoral programs are 
employed to effectively control and eliminate the burden of malaria.  
The history of malaria is important because it gives insight into the best 
measures that can be taken moving forward. It is clear that clinical and public 
health interventions have significantly helped to reduce the burden of malaria 
however these efforts have been successful and enduring in developed nations. 
The little success seen in endemic, developing regions waned over time and 
currently, the burden is much heavier as resistance to interventions is on the rise. 
Although much has been done in health efforts, there is a need for government 






The Economic Case for Malaria 
 
International Funding 
International funding for malaria increased from $100 million to $1.94 
billion between 2000 and 2013. The inception of the Global Fund to Fight AIDS, 
Tuberculosis, and Malaria in 2002 caused a sharp increase in funding (RBM, 
n.d.). Currently, the United States annually pours $522 million, contributing a little 
over 50% of the total international aid. According to WHO, a total of $5.1 billion is 
needed annually to provide interventions globally, however, the total funds for 
malaria do not reach this value (WHO(d), n.d.). The Global Malaria Action Plan 
also estimated that $5-6 billion is needed annually to maintain malaria control 
and work towards eradicating malaria as shown in the figure below. Current 
funding barely reaches $2 billion, thus malaria funding is inadequate. 
Perhaps the biggest player in the international funds for malaria is the 
Global Fund to Fight AIDS, Tuberculosis, and Malaria.  By forging partnerships 
between governments, civil societies, private sectors and communities, the 
Global Fund does a great deal of work in combating disease. According to their 
website, the Global Fund has helped 6.1 million people get access to 
antiretroviral therapies, 11.2 million tests and treatments provided for 
tuberculosis, and 360 million ITNs distributed for malaria prevention (Global Fund 
(b), n.d.). Malaria monetary spending is distributed to a few efforts. 
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Approximately 51% goes to preventative efforts such as ITNs, 25% goes to 
treatment such as ACTs, 13% to health system training, and 11% to engendering 
a supportive environment (Pigott et al, 2012). 
 
 
Figure 3: Inadequate Funds for Malaria 
Source: (RBM), n.d.) 
 
According to Roll Back Malaria, as 90% of the global malaria burden falls 
in Sub-Saharan Africa, it is the recipient of 80% of international aid (RBM, n.d.). 
Funding is generally allocated to regions that suffer the highest morbidity and 
mortality of malaria. A study conducted by Pigott et al (2012) observed that most 
Sub-Saharan Africa countries rely on international aid, whereas malaria endemic 
countries in the Americas generally rely on domestic governments for support 
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(Pigott et al., 2012). During the study period, malaria endemic countries in 
Central America received 11.47% of external aid in compared to 86.89% for Sub-
Saharan Africa (Pigott et al., 2012). Of course, these results are indicative of the 
fact that wealthier countries are more capable and willing to pay for malaria 
support. And as many Sub-Saharan countries continue to struggle with staying 
afloat in the world economy, malaria continues to be a burden. 
In comparison to Sub-Saharan Africa, the malaria endemic regions of 
South America do not experience the heavy morbidity and mortality. Malaria 
cases generally fall in the Amazon Basin in Brazil, Colombia, Bolivia, Peru and 
small region in Ecuador. In 2010, 240 malaria deaths were reported comprising 
only 0.085% of the global mortality total (Cruz et al., 2013). This low number is 
caused by a myriad of factors. First, the parasite prevalent in South America is 
the P. vivax (Oliveira-Ferreira et al., 2010). This strain is less virulent and causes 
milder forms of malaria compared to the P. falciparum prevalent in Sub-Saharan 
Africa. Also, P. vivax is still sensitive to Chloroquine and insecticides that P. 
falciparum has become resistant to. Second, the biodiversity in the region is 
home to the cinchona bark tree that quinine is extracted from. This has opened 
up a good clinical basis to support discovery and development of new 
antimalarial drugs. Moreover, this has also opened up good development in the 
region. Finally, and perhaps most importantly, South America has developed a 
quality health care system that thoroughly responds to epidemics (Cruz et al., 
2013).  It is a clear contrast with Sub-Saharan Africa in that although both 
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regions are endemic to malaria, there are a myriad of development factors that 
differentiate how the disease affects both regions. 
Looking back at the history of malaria, increased methods of interventions 
have proved that the parasite mutates, and as a consequence the virulence 
increases at the cost of higher morbidities and mortalities. Thus, malaria endemic 
countries, generally developing nations, are forced to rely on external aid 
because of failed interventions. It is a cycle of need that lands many nations in 
dependence and Sub-Saharan Africa is a prime example. A recent publication 
looking at the political implications of aid shows that in aid recipient countries, 
there is a disconnection between the government and the people (Moss & Van 
de Walle, 2006).. Because national governments may not be directly accountable 
to its people, in the case of foreign aid, it may not feel that it needs to maintain 
popular legitimacy. Governments are also unlikely to establish institutions to 
assuage problems at hand (Moss & Van de Walle, 2006). Thus if we apply this 
idea to the case for malaria, countries receiving external aid fall into a cycle of 
dependence. This dependence causes governing institutions to take their hands 
off of working to alleviate the burden of malaria. In addition, this also leaves room 
for mal-governance and political corruption as governments may not feel the 
need to maintain popularity with the people as their needs are met by 
international efforts. Of course, discrediting the work done by international aid is 
unfair as millions of lives have been saved by external aid. It is, however, 
important to bring to light the damaging effects of too much money being pumped 
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into aid efforts. If the goal is to alleviate the burden of disease while enhancing 
development, then perhaps increasing outflow of money into these regions may 
not be the best solution. 
 
Complexity of Malaria – Poverty and Disease. 
Currently, there is no one solution that can treat malaria in all endemic 
regions. The complexity of malaria is due to its partnership with poverty. Where 
there is poverty there is disease, as illustrated in Figure 4. Disease and poverty 
constitute a viscous, self-perpetuating cycle that makes treatment complicated. 
 
Figure 4: Geographical Distribution of Malaria and Poverty 




Poverty is a cause of disease. In the case for malaria, poverty exposes 
people to infection (Teklehaimanot & Paola Mejia, 2008). Impoverished dwellings 
are generally favorable for mosquito breeding and are also areas of infection. 
Preventative measures, such as ACTs and LLINs may not be affordable to each 
household leaving many exposed to the infectious bite of the mosquito. 
Healthcare access is also too expensive leaving many untreated and increasing 
the risk of transmission. Migration from urban to rural areas is also a cause of 
disease as it is associated with poverty. Studies show that people who generally 
migrate from rural to urban areas settle in poorly constructed homes in densely 
populated areas also creating an environment favoring mosquito breeding 
(Robert et al., 2003). For example, malaria risk is relatively low in the urban city 
of Nairobi, Kenya. However, within the city is the densely populated slum of 
Kibera. Kibera is teeming with high rates of malaria as living conditions 
accommodate mosquito and parasite breeding (Kasili et al., 2009). Malaria 
transmission and infection rates in Kibera are consequently high. A recent study 
validated the association between poverty and disease showing that causality 
between the two may run in the opposite direction. In this multi-regional study, 
higher incomes showed to increase prevention and treatment of malaria, 
contributing to the correlation between poverty and disease (Datta & Reimer, 
2013). 
Poverty is also a cause of poor nutritional status. It is well known that poor 
nutrition contributes to disease. As Shankar et al (2000) demonstrated, less food 
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consumption leads to protein energy malnutrition which increases the morbidity 
and mortality of malaria. There are numerous nutritional studies that highlight the 
importance of specific vitamins and minerals that play a role in reducing severity 
of disease.  Trials of vitamin A and Zinc supplementation show that these 
nutrients can reduce clinical malaria attacks and reduce the severity of disease. 
A recent study conducted in Ghana among children demonstrated that the group 
given Vitamin A supplementation had 27% less infection of malaria than the 
control group (Owusu-Agyei et al., 2013). A study conducted in 2008 in Burkina 
Faso also showed that Vitamin A supplementation, along with Zinc, reduced risk 
of fever and severe clinical malaria among children (Zeba et al., 2008). Nutrition 
clearly plays a role in alleviating the burden of disease. The exact mechanism 
was shown in a study by Serghides et al. demonstrating that Vitamin A helps in 
the up-regulation of CD36 expression, which aids in phagocytosis and may 
activate substances that which inhibit the inflammatory responses that are 
associated with severe and cerebral malaria (Serghides & Kain, 2002). A study 
by Anuraj Shankar (2000) et al also showed that Zinc deficiency exacerbates 
diseases that rely on macrophage killing of infected cells. Malaria, as 
aforementioned in Chapter 1, is such a disease. Statistical data shows that 
children from poorer households in urban areas are more likely to be 
malnourished compared to children from poorer households in rural areas (Fotso 
& Kuate-Defo, 2006). This hold true as rural households obtain food through 
subsistence farming whereas households in urban areas depend on an income 
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to purchase food. As many economically disadvantaged populations are 
disposed to be undernourished, predisposition to malaria infection is a 
consequence. 
Malaria is a cause of poverty. In many rural regions in Sub-Saharan 
Africa, malaria infection means time lost to work and resulting in less food 
consumption (Teklehaimanot & Paola Mejia, 2008). In urban areas, this is also 
true as less money is earned and less food is purchased. The general idea is that 
households suffer when a productive member falls ill with malaria. If we look at 
the context of the disease in a typical household in sub-Saharan Africa, if a 
productive member falls ill then household labor is diverted from activities that 
generate income and placed into caregiving if healthcare is unavailable. It is also 
common that children are withdrawn from school as no income results in no 
tuition thus reducing the chance of a proper future income (Purdy, Robinson, 
Wei, & Rublin, 2013). Reduced income follows perpetuating the economic 
disposition of such a household. 
The cycle of poverty and disease is felt most by vulnerable groups. As 
most malaria mortalities are among children, their first five years are crucial in 
survival and development. Immune development against malaria is also crucial in 
this stage. Malnutrition as a result of poverty is highly associated with child 
mortality. Pelletier et al. found that mild to moderate malnutrition increased the 
likelihood of mortality and there is also an epidemiologic synergism between 
disease morbidity and malnutrition (Pelletier, Frongillo, & Habicht, 1993). This is 
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consistent with current data that shows malaria mortality is mostly among 
children under the age of five as aforementioned. As for pregnant women, 
malaria has detrimental effects on both the mother and the unborn child. As 
mentioned in previous chapters, pregnancy increases the likelihood of malarial 
infection as the immune system is slightly depressed. Pregnant women suffering 
from malaria experience severe symptoms, they have higher rates of miscarriage 
and premature delivery, and their unborn children typically become low-birth-
weight neonates (Schantz-Dunn & Nour, 2009). The result of low-birth-weight 
babies also feeds into the cycle of poverty and disease as it is associated with 
infant mortality, morbidity, growth retardation, poor cognitive development, and 
chronic diseases (Mmbando et al., 2008).  Children who suffer repeated 
episodes of malaria are also found to demonstrate reduced learning. This also 
leads to lower levels of human capital among households in malaria-endemic 
communities, perpetuating the cycle of poverty and disease (Malaney, Spielman, 
& Sachs, 2004). 
This complex cycle of disease and poverty may be the reason that there 
have been numerous malaria eradication and control programs that have not 
reached their objectives in sub-Saharan Africa. Malaria is not a stand-alone 
disease. There are numerous causative factors and confounding factors that lead 





Figure 5: The Cycle of Poverty and Disease 
Source: (Fondazione Sclavo, n.d.) 
 
Why previous programs failed 
Since the discovery of the etiology and pathology of malaria there have 
been numerous programs to eradicate the disease. As mentioned in the History 
of Malaria Section, the Global Malaria Eradication Program established in 1955 
eventually collapsed when the goal of eradication wasn’t achieved in many 
areas. Although many regions saw malaria eradication, other regions like India 
saw a heavy resurgence as economic and financial crises impeded maintenance 
and control declined. Due to unclear reasons, the Sub-Saharan region, heaviest 
in morbidity and mortality, was virtually untouched with the eradication efforts. As 
Nájera et al (2011) concludes, the failure of this effort highlights that there is no 
single strategy that will be applicable everywhere. In addition, long term 
commitment includes community involvement, health systems integration, and 
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development of reliable and effective surveillance systems along with sustained 
interventions. Malaria must be approached with a holistic solution to assuage the 
burden of the disease while also spurring development. Poverty must be relieved 
together with disease. 
 
Funding the vaccine 
One of the most heavily funded interventions is the malaria vaccine being 
developed by GSK and PATH. To date, the Bill and Melinda Gates foundation 
has donated $1 billion to the development of the RTS,S vaccine (Malaria Vaccine 
Initiative, n.d.). As aforementioned, the complex cycle of disease and poverty will 
not be eradicated simply by a vaccine. The amount of money pumped into its 
development is more than enough to implement programs that focus on 
alleviating the burden of poverty, decreasing the likelihood of disease. This 
money could be better used to build homes so families do not have to sleep in 
breeding places of mosquito larvae. The money could also be used to fund 
drainage programs, city cleanups, and malaria education so that the burden of 
malaria can be alleviated as seen throughout history. 
Copious funds for the vaccine are also not justified by the small 
percentage of protective effect the phase III trials have reported. Although it is 
intended to be used in addition to already established efforts, trial results don’t 
warrant the heavy funds. As previous efforts have shown, killing the vector will 
not help and new means of inhibiting the parasite leaves room for mutations. It is 
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also important to establish clear vaccine efficacy before introducing it to endemic 
regions. There shouldn’t be an imperfect vaccine as it may interfere with the 
already present immunity acquired by populations in endemic regions, and also 
poses a risk for the emergence of new resistance, contributing to the resistance 
of almost all anti-malarial interventions. 
 
Financing Malaria 
There is supporting evidence that more funding results in better outcomes 
for malaria control. A study conducted by Purdy et al. (2013) attempts to create 
incentives to increase funding by projecting that malaria reduction and 
elimination will save about $208.6 billion, globally, between 2013 and 2035. The 
study aimed to show that attaining funding required to meet international targets 
would generate economic improvements by eliminating the disease. Another 
study in Gambia noted a decline in malaria with increased interventions and 
recommended an intensification of control interventions by increasing funding 
(Ceesay et al., 2010). The reality of these conclusions is that they are simply 
theories projected by known factors. A recent study assessed the association 
between program funding, per person at risk, ITN coverage, and declines in 
malaria morbidity and mortality (Korenromp et al., 2013). It concluded that the 
solution would be to maximize donor funding and properly allocate it to countries 
with highest continued need. It is important to realize the complexity of the 
disease as well as understand that there are limitations in analyzing numbers as 
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accuracy of case reporting may not be reliable in certain regions for various 
reasons. Moreover, associations don’t necessarily mean causality. There are 
numerous factors that that define the efficacy of these heavily funded 
interventions. According to Gething et al (2014), more systematic, timely, and 
empirical approaches are needed to track the transmission, morbidity, and 
mortality of the disease as heavily funded malaria control activities increase in 
sub-Saharan Africa. 
Antimalarial drugs are heavily funded to support endemic sub-Saharan 
regions. Since 2002 when WHO endorsed ACTs, the drugs were met with a very 
high demand. However, over the years this demand has been unstable due to 
financing and programmatic uncertainties (Shretta & Yadav, 2012). Within the 
ACT market, grants in the public sector from the Global Fund contributes to 
about 1/3 of the entire market (Maxmen, 2012). For sub-Saharan African regions, 
the need for external aid aggravates the malaria burden by creating new avenues 
for more roadblocks. Financing uncertainties, particularly with the Global Fund, 
include lengthy cycles of review of grants, approvals, and disbursements 
(Maxmen, 2012). These issues also bleed into other malaria control markets. In 
Ghana, a delay in the receipt of funds resulted in a 12 month delay for IRS and 
LLIN programs (Shretta & Yadav, 2012). Unfortunately the malaria parasite and 
the mosquitoes do not pause for these processes to take place. The result is 
continued morbidities and mortalities while funds await disbursements. The 
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reality is that these economic processes must take place for action to be 
sustained. 
The question that must be repeatedly asked is what problem is the malaria 
community ultimately trying to solve? These external aid impediments wouldn’t 
exist if endemic countries were able to self-finance their own malaria efforts. 
Unfortunately, this is not so, and companies that create malaria interventions 
must receive profit for their products, bought by organizations such as the Global 
Fund. If we want to establish a global economy where developed drugs can be 
priced as asking value then investing in developing the “underdeveloped” nations 
comes first. The issue is that the regions in most need are not able to play in the 
global world economy. Unless malaria efforts do not come with a price tag then 
there will be confounding factors impeding the global eradication goal. Moreover, 
as funding never seems to be adequate, there needs to be a review and analysis 
on the efficacy and practicability of the current interventions that billions of dollars 





Discussion and conclusion: 
 
In September 2013, the Multisectoral Action Framework for Malaria was 
launched in New York. This program is a collaboration between the Roll Back 
Malaria Partnership and the United Nations Development Programme that aims 
to coordinate action among various development sectors to combat malaria. The 
Framework urges policymakers and healthcare practitioners to increase 
partnerships to speed up the socio-economic development and current malaria 
controls. By working from the premise that malaria is associated with poor socio-
economic development, marginalization, and exploitation of fragile markets, the 
program aims to combat malaria and poverty simultaneously. The history of 
malaria demonstrates that eradication was successful in regions where efforts 
were targeted on broad socio-economic determinants such as living conditions, 
education, and protecting the environment. With this in mind, an integration of a 
multisectoral dimension, as proposed by the Roll Back partnership to combating 
malaria means added value to the outcome as there are a wide range of 
stakeholders engaged. (RBM, n.d.). The available data on malaria burden and its 
relation to poverty, must translate into action. Malaney et al (2004) demonstrates 
that macroeconomic studies find that in endemic regions, malaria is responsible 
for reducing economic growth by more than 1% each year. One the other hand, 
microeconomic studies, aggregating the cost per case, finds that economic 
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growth is reduced by less than 1%. The gap between these estimates, as 
concluded by Malaney et al (2004), suggests that other malaria associated 
factors make the burden greater than just the sum of individual cases. The study 
asserts that these results must be taken into consideration by governments and 
healthcare policymakers. There are numerous studies that continue to assert that 
the complexity of malaria warrants a comprehensive approach to eradication. As 
previously discussed, already known data must be translated into action. This 
action can only be fully taken with a partnership between various sectors aiming 
to reduce the burden of disease by also alleviating the burden of poverty. 
The limitations of current malaria treatments in Sub-Saharan Africa are beyond 
clinical interventions and call for economic development. In comparison to South 
America, it is clear that development is a key factor preventing thorough malaria 
eradication. Likewise, malaria eradication in developed nations such as the 
United States serves as an example of the potential efficacy of interventions if 
development in endemic regions was achieved first. The Multisectoral Action 
Framework for Malaria is currently a prime example of a holistic approach to treat 
malaria in the integration of healthcare efforts, economic efforts, and government 
efforts in theory. Looking back throughout history, multisectoral efforts take years 
to demonstrate effectiveness. With the myriad of independent global aid 
organizations and the efforts already producing results, the additional concept of 
a holistic and multisectoral approach should result in significant reduction of 
malaria morbidity and mortality over the next few years. Of course, only time will 
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tell. Nevertheless, the complexity and the burden of the disease warrants 
continued monitoring and sustained global effort in eradication by employing 
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